里昂發表報告，指國藥控股(01099.HK)去年末季業績呈逐漸改善，因至去年底止內地醫藥打貪影響逐漸消退。去年末季公司收入按季升3.9%，純利按季升48.5%至30億元人民幣。
報告稱，公司專注盈利擴張，料其醫療器材製造新興業務將驅動利潤擴張。重申「買入」評級，目標價由27.1元略降至27元。
《大行報告》里昂微降國藥(01099.HK)目標價至27元 評級「買入」
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.